SEARCH RESULTS FOR:

Pharma & Life Sciences
China

Conrad Bucheleres, Wei Hong & Yong Zhang

AZELIS GREATER CHINA
Azelis sources an increasing array of speciality chemicals in China and distributes across the world.
United States
Pharma & Life Sciences

Peter Parker

MANAGING GENERAL PARTNER, BIOINNOVATION CAPITAL AND CO-FOUNDER AND DIRECTOR, LABCENTRAL
United States Biopharmaceuticals 2018
LabCental offers life science companies in Massachusetts at an early stage the facilities they need to develop
Mexico
Petrochemicals & Chemicals

Abraham Klip Moshinsky

GENERAL DIRECTOR, UNIGEL MEXICO
Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
Unigel Mexico laments the country’s inadequate feedstock production.
Petrochemicals & Chemicals
Singapore

Lieven Vander Elstraeten

CEO, BERTSCHI SINGAPORE PTE LTD
Singapore Chemicals 2018
Bertschi Singapore will to continue the rapid expansion of its capacity and services on Jurong Island.
United States
Pharma & Life Sciences

David Cory

CEO, EIGER BIOPHARMACEUTICALS
United States Biopharmaceuticals 2018
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Mining
Chile

Chile Mining 2018 Expomin Official Investment Guide

Mexico
Petrochemicals & Chemicals

Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release

United States
Pharma & Life Sciences

Barbara Weber

CEO, TANGO THERAPEUTICS
United States Biopharmaceuticals 2018
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
United States
Pharma & Life Sciences

United States Biopharmaceuticals 2018 Pre-Release

Mining
Peru

Ángel Tobar

GENERAL MANAGER ANDEAN REGION, EPIROC
Peru Mining 2018 Pre-Release
"Battery-charging technologies should be used in a similar way to cellphones, regardless of the brand"

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL